{"filing":{"accession_number":"0001104659-26-116736","cik":"0001868279","ticker":"AVBP","company_name":"ArriVent BioPharma, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"tm2627799d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/tm2627799d1_8k.htm"},"events":[{"id":35964,"run_id":33153,"accession_number":"0001104659-26-116736","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"ArriVent announced the publication of Phase 1b clinical trial results for firmonertinib in Cancer Cell, highlighting efficacy and safety data in EGFR PACC-mutant NSCLC. This is a material clinical milestone for a clinical-stage biopharmaceutical company—the publication of positive Phase 1b data supporting advancement toward Phase 3 trials represents a significant operational and strategic development. While not a traditional earnings release, M\u0026A activity, or governance event, this clinical publication is material to investors assessing the company's pipeline progress and therapeutic potential.","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40206,"accession_number":"0001104659-26-116736","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ArriVent announced the publication of Phase 1b clinical trial results for firmonertinib in Cancer Cell, highlighting efficacy and safety data in EGFR PACC-mutant NSCLC. This is a material clinical milestone for a clinical-stage biopharmaceutical company—the publication of positive Phase 1b data supporting advancement toward Phase 3 trials represents a significant operational and strategic development. While not a traditional earnings release, M\u0026A activity, or governance event, this clinical publication is material to investors assessing the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:09:45.623087+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40206,"accession_number":"0001104659-26-116736","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ArriVent announced the publication of Phase 1b clinical trial results for firmonertinib in Cancer Cell, highlighting efficacy and safety data in EGFR PACC-mutant NSCLC. This is a material clinical milestone for a clinical-stage biopharmaceutical company—the publication of positive Phase 1b data supporting advancement toward Phase 3 trials represents a significant operational and strategic development. While not a traditional earnings release, M\u0026A activity, or governance event, this clinical publication is material to investors assessing the company's pipeline progress and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T12:09:45.623087+00:00","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-10-19"}]}